MedTrace Logo

A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza

NCT03570359 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2023-01-04

No results posted yet for this study

Summary

The aim of the study is to assess the safety of inhaled SNG001 and the ability of inhaled SNG001 to 'switch on' the cells' anti-viral defences in patients with chronic obstructive pulmonary disease (COPD). The study consist of two parts.

Part 1 will assess the safety of inhaled SNG001 in ten patients with stable COPD.

Part 2 will assess efficacy and safety of inhaled SNG001 in 120 patients with COPD with a cold or COPD exacerbation.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Interferon Beta-1A

Interferon Beta-1A via inhalation

OTHER

Placebo

Placebo via inhalation

Sponsors & Collaborators

  • Synairgen Research Ltd.

    lead INDUSTRY

Principal Investigators

  • Tom Wilkinson · University Hospital Southampton NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-29
Primary Completion
2020-05-05
Completion
2020-05-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03570359 on ClinicalTrials.gov